Hepatitis D is also known as the “delta hepatitis”. It is a liver infection that is caused by the hepatitis D virus (HDV). HDV usually infects people who are already infected with the hepatitis B virus (HBV), because the HDV is an incomplete virus which requires the helper function of HBV to replicate. Hepatitis D can be either a short-term, acute infection or a long-term, chronic infection. HDV can be transmitted through percutaneous or by mucosal contact with infectious blood and can be acquired either as a co-infection with HBV or as a superinfection in people with HBV infection. As of now, there is no vaccine against HDV.
According to the CDC, it is estimated that approximately 5% of people with the chronic HBV infection are co-infected with HDV, resulting in a total of 15 to 20 million persons infected with HDV, globally. However, this is a broad global estimation, but many countries do not report the prevalence of HDV.
This report by Mordor Intelligence provides extensive insights of the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world, are provided, with data obtained from multiple sources. The report also comprises of a list of key sponsors, having pipeline products for the concerned market.
The report will cover the analysis of trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stake holders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation- by Phase
6.1 Phase III Product Candidates
6.2 Phase II Product Candidates
6.3 Phase I Product Candidates
7. Clinical Trials Segmentation- by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Info graphic Charts and Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence